FDA Should Resolve Patent Dispute In AmCell Case, Delaware Court Rules
This article was originally published in The Gray Sheet
Executive Summary
FDA should clarify whether an exemption in U.S. patent law protects AmCell Corp. from a patent infringement suit by Nexell Therapeutics, according to a summary judgment by the federal district court in Wilmington, Delaware.